Operating Expenses
Share-Based Compensation Expense
Pfizer Share-Based Compensation Expense increased by 20.9% to $272.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 60.0%, from $170.00M to $272.00M. Over 4 years (FY 2021 to FY 2025), Share-Based Compensation Expense shows a downward trend with a -9.3% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
Metric ID:
axp_share_based_compensation_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $221.00M | $293.00M | $496.00M | $86.00M | $287.00M | $135.00M | $364.00M | $105.00M | $148.00M | $151.00M | $121.00M | $220.00M | $206.00M | $274.00M | $177.00M | $170.00M | $203.00M | $201.00M | $225.00M | $272.00M |
| QoQ Change | — | +32.6% | +69.3% | -82.7% | +233.7% | -53.0% | +169.6% | -71.2% | +41.0% | +2.0% | -19.9% | +81.8% | -6.4% | +33.0% | -35.4% | -4.0% | +19.4% | -1.0% | +11.9% | +20.9% |
| YoY Change | — | — | — | — | +29.9% | -53.9% | -26.6% | +22.1% | -48.4% | +11.9% | -66.8% | +109.5% | +39.2% | +81.5% | +46.3% | -22.7% | -1.5% | -26.6% | +27.1% | +60.0% |
Range$86.00M – $496.00M
CAGR+4.5%
Avg YoY Growth+11.3%
Median YoY Growth+17.0%
Current Streak2 quarters growth
Share-Based Compensation Expense at Other Companies
Frequently Asked Questions
- What is Pfizer's share-based compensation expense?
- Pfizer (PFE) reported share-based compensation expense of $272.00M in Q1 2026.
- How has Pfizer's share-based compensation expense changed year-over-year?
- Pfizer's share-based compensation expense increased by 60.0% year-over-year, from $170.00M to $272.00M.
- What is the long-term trend for Pfizer's share-based compensation expense?
- Over 4 years (2021 to 2025), Pfizer's share-based compensation expense has grown at a -9.3% compound annual growth rate (CAGR), from $1.18B to $799.00M.